Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-vfjqv Total loading time: 0 Render date: 2024-04-29T07:51:28.747Z Has data issue: false hasContentIssue false

Chapter 8 - Attention-Deficit/Hyperactivity Disorder in Prader-Willi Syndrome

Published online by Cambridge University Press:  26 May 2022

By
Deepan Singh
Edited by
Deepan Singh
Deepan Singh
Affiliation:
Maimonides Medical Center in Brooklyn
Get access

Summary

Attention-deficit/hyperactivity disorder (ADHD) is common in patients with PWS. Symptoms of ADHD are varied and some patients might present with more inattention and less hyperactivity. Poor impulse control (impulsivity) is a component of ADHD that can lead to disruptive behavior such as aggression. Medications are a highly effective means of reducing ADHD symptoms. This chapter describes the phenomenon of ADHD in PWS. In addition, the wide variety of stimulants as well as non-stimulant medicines that are well studied and shown to be effective in the management of ADHD are discussed. Shared decision-making between caregivers and clinicians after reviewing the particular needs of the patient and side-effect profile of ADHD medications is recommended for appropriate treatment. In addition to medications, behavioral therapy is helpful for anxiety, parent–child interaction issues, depression, or oppositional behaviors that may present along with ADHD. Early detection and treatment of ADHD may improve educational outcomes and reduce behavioral problems such as aggression associated with PWS.

Keywords

ADHDstimulantsnon-stimulantsmethylphenidateamphetamineatomoxetineinattentionhyperactivityimpulsivityside effects
Type
Chapter
Information
Neuro-behavioral Manifestations of Prader-Willi Syndrome
A Guide for Clinicians and Caregivers
 , pp. 68 - 76
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Butler, MG. Clinical and genetic aspects of the 15q11.2 BP1-BP2 microdeletion disorder. J Intellect Disabil Res 2017;61(6):568–79.CrossRefGoogle ScholarPubMed
American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM–5).Google Scholar
Samea, F, Soluki, S, Nejati, V, Zarei, M, Cortese, S, Eickhoff, SB, et al. Brain alterations in children/adolescents with ADHD revisited: A neuroimaging meta-analysis of 96 structural and functional studies. Neurosci Biobehav Rev 2019;100:1–8.Google Scholar
Manning, KE, Tait, R, Suckling, J, Holland, AJ. Grey matter volume and cortical structure in Prader-Willi syndrome compared to typically developing young adults. Neuroimage Clin 2018;17:899–909.CrossRefGoogle ScholarPubMed
Luck, C, Vitaterna, MH, Wevrick, R. Dopamine pathway imbalance in mice lacking Magel2, a Prader-Willi syndrome candidate gene. Behav Neurosci 2016;130(4):448–59.Google Scholar
Biederman, J. Attention-deficit/hyperactivity disorder: A selective overview. Biol Psychiatry 2005;57(11):1215–20.Google Scholar
Del-Ponte, B, Anselmi, L, Assunção, MCF, Tovo-Rodrigues, L, Munhoz, TN, Matijasevich, A, et al. Sugar consumption and attention-deficit/hyperactivity disorder (ADHD): A birth cohort study. J Affect Disord 2019;243:290–6.CrossRefGoogle ScholarPubMed
Tansriratanawong, S, Louthrenoo, O, Chonchaiya, W, Charnsil, C. Screen viewing time and externalising problems in pre-school children in northern Thailand. J Child Adolesc Ment Health 2017;29(3):245–52.Google Scholar
Levelink, B., van der Vlegel, M., Mommers, M., Gubbels, J., Dompeling, E., Feron, F., van Zeben-van der Aa, D., Hurks, P., & Thijs, C. (2021). The Longitudinal Relationship Between Screen Time, Sleep and a Diagnosis of Attention-Deficit/Hyperactivity Disorder in Childhood. Journal of attention disorders, 25(14), 2003–2013.Google Scholar
Tamana, SK, Ezeugwu, V, Chikuma, J, Lefebvre, DL, Azad, MB, Moraes, TJ, et al. Screen-time is associated with inattention problems in preschoolers: Results from the CHILD birth cohort study. PLoS ONE 2019;14(4):e0213995.Google Scholar
Thapar, A, Cooper, M. Attention deficit hyperactivity disorder. Lancet 2016;387(10024):1240–50.Google Scholar
Nielsen, DS, Krych, Ł, Buschard, K, Hansen, CHF, Hansen, AK. Beyond genetics. Influence of dietary factors and gut microbiota on type 1 diabetes. FEBS Lett 2014;588(22):4234–43.CrossRefGoogle ScholarPubMed
Fernández de la Cruz, L, Simonoff, E, McGough, JJ, Halperin, JM, Arnold, LE, Stringaris, A. Treatment of children with attention-deficit/hyperactivity disorder (ADHD) and irritability: Results from the multimodal treatment study of children with ADHD (MTA). J Am Acad Child Adolesc Psychiatry 2015;54(1):62–70.e3.Google Scholar
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999;56(12):1073–86.Google Scholar
Dykens, E, Shah, B. Psychiatric disorders in Prader-Willi syndrome: Epidemiology and management. CNS Drugs 2003;17(3):167–78.Google Scholar
Cortese, S, Adamo, N, Del Giovane, C, Mohr-Jensen, C, Hayes, AJ, Carucci, S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. Lancet Psychiatry 2018;5(9):727–38.Google Scholar
Hudson, JI, McElroy, SL, Ferreira-Cornwell, MC, Radewonuk, J, Gasior, M. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: A randomized clinical trial. JAMA Psychiatry 2017;74(9):903–10.Google Scholar
Childress, AC, Chow, H. Amphetamine extended-release oral suspension for attention-deficit/hyperactivity disorder. Expert Rev Clin Pharmacol 2019;12(10):965–71.Google Scholar
Cortese, S, D’Acunto, G, Konofal, E, Masi, G, Vitiello, B. New formulations of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: Pharmacokinetics, efficacy, and tolerability. CNS Drugs 2017;31(2):149–60.CrossRefGoogle ScholarPubMed
Gadde, KM, Martin, CK, Berthoud, H-R, Heymsfield, SB. Obesity: Pathophysiology and management. J Am Coll Cardiol 2018;71(1):69–84.Google Scholar
Charlotte, W, Loshak, H, Dulong, C. Withdrawal Management and Treatment of Crystal Methamphetamine Addiction in Pregnancy: A Review of Clinical Effectiveness and Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2019.Google Scholar
Warren, AE, Hamilton, RM, Bélanger, SA, Gray, C, Gow, RM, Sanatani, S, et al. Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry. Can J Cardiol 2009;25(11):625–30.Google Scholar
Moran, LV, Ongur, D, Hsu, J, Castro, VM, Perlis, RH, Schneeweiss, S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med 2019;380(12):1128–38.CrossRefGoogle ScholarPubMed
Singh, D, Wakimoto, Y, Filangieri, C, Pinkhasov, A, Angulo, M. Guanfacine extended release for the reduction of aggression, attention-deficit/hyperactivity disorder symptoms, and self-injurious behavior in Prader-Willi syndrome: A retrospective cohort study. J Child Adolesc Psychopharmacol 2019;29(4):313–17.CrossRefGoogle ScholarPubMed
Nasser, A, Liranso, T, Adewole, T, Fry, N, Hull, JT, Chowdhry, F, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (Viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther 2020;42(8):1452–66.Google Scholar
Clemow, DB, Bushe, CJ. Atomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients. J Psychopharmacol (Oxford) 2015;29(12):1221–30.Google Scholar
Drugs@FDA: FDA-approved drugs. New drug application (NDA): 021411 [Internet]. [cited June 21, 2021]. Available from www.accessdata.fda.gov/drugsatfda_docs/label/2020/021411s049lbl.pdfGoogle Scholar
Drugs@FDA: FDA-approved drugs. New drug application (NDA): 211964 [Internet]. [cited June 21, 2021]. Available from www.accessdata.fda.gov/drugsatfda_docs/label/2021/211964s000lbl.pdfGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×